Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: Correlation between dyslipidaemia and steroid hormone alterations

AIDS

Volumn 13, Issue 16, 1999, Pages 2251-2260

  Christeff, Névéna ^a   Melchior, Jean Claude ^b   De Truchis, Pierre ^b   Perronne, Christian ^b   Nunez, Emmanuel A ^c   Gougeon, Marie Lise ^a  

^a CNRS   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Atherogenic lipids; Cortisol; Dehydroepiandrosterone; Highly active antiretroviral therapy; HIV infected men; Lipodystrophy

Indexed keywords

ANDROSTANOLONE; ANDROSTENEDIONE; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROCORTISONE; LIPID; LOW DENSITY LIPOPROTEIN; PRASTERONE; PRASTERONE SULFATE; STEROID HORMONE; TESTOSTERONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY FAT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCORTISONE BLOOD LEVEL; LIPID BLOOD LEVEL; LIPODYSTROPHY; LIPOGENESIS; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANDROGENS; ANTI-HIV AGENTS; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HUMANS; HYDROCORTISONE; HYPERLIPIDEMIAS; INSULIN; LEPTIN; LIPODYSTROPHY; MALE; MIDDLE AGED;

EID: 0009560881     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199911120-00007     Document Type: Article

References (37)

1. 1. Cameron DW, Heath-Chiozzi M, Danner S, et al Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998, 351:543-549.
2. 2. Miller KK, Daly PA, Sentochink JD, et al. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis 1998, 27:68-72.
3. 3. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998, 12:F37-39.
4. 4. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. 'Buffalo hump' in men with HIV-1 infection, Lancet 1998, 351:867-870.
5. 5. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with prolease inhibitors. Lancet 1997, 350:1596.
6. 6. Herry I, Bernard L, de Truchis P, Perronne C. Hypertrophy of the breast in a patient with indinavir. Clin Infect Dis 1997, 25:937-938.
7. 7. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875.
8. 8. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV-1-protease inhibitors. AIDS 1998, 12:F51-F58.
9. 9. Saint-Marc T, Martin-Poizot I, Partisani M, Fabre J, Touraine JL. A syndrome of lipodystrophy in patients receiving a stable nucleoside-analogue therapy. VIth Conference on Retroviruses and Opportunistic Infections. Chicago, January 1999 [Abstract 79-653].
10. 10. Nunez EA, Christeff N. Steroid hormones, cytokines, lipid and metabolic disturbances in HIV infection. In: The endocrinology and metabolism of HIV infection. Norbiato G (editor). London: BaillièreTindall; 1994. pp. 803-824.
11. 11. Christeff N, Gharakhanian S, Thobie N, Rozenbaum W, Nunez AE. Evidence for changes in adrenal and testicular steroids during HIV infection. J AIDS 1994, 5:841-846.
12. 12. Christeff N, Gherbi N, Mammes O, et al. Serum Cortisol and DHEA concentrations during HIV infection. Psychoneuroendocrinology 1997, 22:S11-18.
13. 13. Christeff N, Melchior JC, Mammes O, et al. Correlation between increased cortisol/DHEA ratio and malnutrition in HIV-positive men. Nutrition 1999, 15:534-539.
14. 14. Rudel LL, Parks JS, Johnson FL, Babiak J. Low density lipoproteins in atherosclerosis. J Lipid Res 1996, 27:465-474.
15. 15. Melby JM, Wennhold AR, Nelson DH. Glucocorticoid-induced lipid changes in rat liver microsomes. Endocrinology 1981, 109:920-923.
16. 16. Nestler JE, Clore JN, Blackard WC. Metabolism and actions of dehydroepiandrosterone in humans. J Steroid Biochem Molec Biol 1991, 40:599-605.
17. 17. Mooradian AD, Morley JE, Korenman SC. Biological actions of androgens. Endocrinol Rev 1987, 8:1-28.
18. 18. Oertel GW, Benes P. The effect of steroids on glucose-6-phosphate dehydrogenase. J Steroid Biochem 1972, 3:493-496.
19. 19. Shepherd A, Cleary MP. Metabolic alteration after dehydroepiandrosterone treatment in Zucker rats. Am J Physiol 1984, 246:E123-128.
20. 20. Haffner SM, Mykkänen L, Valdez RA, Katz MS. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 1993, 77:1610-1615.
21. 21. Clore JN. Dehydroepiandrosterone and body fat. Obesity Res 1995, 3:6135-6165.
22. 22. Nestler JE, Beer NA, Lakubowicz DJ, Beer RM. Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men. J Clin Endocrinol Metab 1994, 78:549-554.
23. 23. Berdanier CD, Wundeman R, Tobin RB. Further studies on the role of adrenal hormones in responses of rats to meal-feeding. J Nutr 1976, 106:1791-1800.
24. 24. Tan JT, Patel BK, Kaplan LM, Koenig JI, Hooi SC. Regulation of leptin expression and secretion by corticosteroids and insulin. Endocrine 1998, 8:85-92.
25. 25. Ottosson M, Vikman-Adolfsson K, Enerböck S, Olivecrona G, Björntorp P. The effects of cortisol on the regulation of lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab 1994, 79:820-825.
26. 26. Xu X, De Pergola G, Björntorp P. The effects of androgens on the regulation of lipolysis in adipose precursor cells. Endocrinology 1990, 126:1229-1234.
27. 27. Feingold KR, Soued M, Serio MK, et al. Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinology 1989, 125:267-274.
28. 28. Grunfeld C, Soued M, Adi S, et al. Evidence for two classes of cytokines that stimulate hepatic lipogenesis: relationships among tumor necrosis factor, interleukin-1 and interferon-alpha. Endocrinology 1990, 127:46-54.
29. 29. Feingold KR, Adi S, Staprans I, et al. Diet affects the mechanisms by which TNF stimulates hepatic triglyceride production. Am J Physiol 1990, 259:E177-184.
30. 30. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045-1052.
31. 31. Carr A, Samaras K, Chrisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 352:1881-1883.
32. 32. Toma E Therrien R. Gynecomastia during indinavir antiretroviral therapy in HIV infection. AIDS 1998, 12:681-682.
33. 33. Kalimi M, Shafagoj Y, Loria R, Padgett D, Regelson W. Anti-glucocorticoid effects of dehydroepiandrosterone (DHEA). Mol Cell Biochem 1994, 131:99-104.
34. 34. Hensen PA, Man DH, Notle LA, Chen M, Holloszy JO. DHEA protects against obesity and muscle insulin resistance in rats fed a high-fat diet. Am J Physiol 1997, 273:R1704-1708.
35. 35. Barrett-Connor E, Khaw KT, Yen SSC. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 1986, 315:1519-1524.
36. 36. Gallet B, Pulik M, Genet P, Chedin P, Hiltgen P. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998, 351:1958-1959.
37. 37. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998, 351:1328.